Evaluation of combination therapy of high-dose toremifene and oral chemotherapy

• Published in: Gan to kagaku ryoho Vol. 34; no. 7; p. 1147
• Main Authors: Murakami, Shigeki, Yamamoto, Yasuhisa
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.07.2007
• Subjects: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Capecitabine; Cyclophosphamide - administration & dosage; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Floxuridine - administration & dosage; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Lymph Nodes - pathology; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Oxonic Acid - administration & dosage; Quality of Life; Skin Neoplasms - drug therapy; Skin Neoplasms - secondary; Tegafur - administration & dosage; Toremifene - administration & dosage
• ISSN: 0385-0684

High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer. However, some reports show that combination therapy of high-dose toremifene and chemotherapy exhibits additive effects. Twelve patients were given oral chemotherapy (capecitabine, 5'-DFUR+CPA, S-1) with high-dose toremifene. The overall response rate was 41.7%, in addition to 58.3% with no change beyond three months. Adverse events were restricted to headache, stomatitis and nausea. Average time to progressive (TTP) was 5.8 months. It was shown that high-dose toremifene and oral chemotherapy were useful for breast cancer recurrence without severe side effects.